Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients

Abstract

PVT1, which maps to chromosome 8q24, is a copy number amplification-associated long non-coding RNA. Overexpression of PVT1 is a powerful predictor of tumor progression and patient survival in a diverse range of cancer types. However, the association between PVT1 and hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to examine the expression pattern of PVT1, and its clinical significance in HCC. Between 2003 and 2012, reverse transcription-quantitative polymerase chain reaction was used to determine the expression levels of PVT1 in two independent cohorts: Cohort one, 58 HCC resection samples; and cohort 2, 214 HCC transplant samples. Additionally, the correlation between PVT1 expression levels and clinical parameters and outcomes was analyzed. The relative expression levels of PVT1 were significantly higher in cancerous tissues compared with the corresponding non-cancerous tissues (cohort one, P=0.0016; cohort two, P=0.0274). Furthermore, overexpression of PVT1 was associated with a higher serum α-fetoprotein expression level (P=0.011) and a higher recurrence rate (P=0.004). Kaplan-Meier analysis indicated that the patients with high PVT1 expression exhibited poor recurrence-free survival (P=0.021), and multivariate analysis demonstrated that high levels of PVT1 expression are an independent predictor for HCC recurrence (P=0.042; hazard ratio, 1.653). Thus, the high expression levels of PVT1 in HCC may serve as a novel biomarker for predicting tumor recurrence in HCC patients, and as a potential therapeutic target.

Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells

“…In several cancers, PVT1 is found to be upregulated in cancer tissues than in adjacent normal tissues, and acts to induce cell proliferation and suppress apoptosis (21)(22)(23). In addition, overexpression of PVT1 is involved in cancer resistance to chemotherapy.…”

Increased LncRNA PVT-1 is associated with tumor proliferation and predicts poor prognosis in cervical cancer

“…Long non-coding RNAs (lncRNAs) (i.e., evolutionarily conserved non-coding RNAs that are longer than 200 nucleotides and are not translated into a protein) [5,6] exert regulatory functions in cellular processes, such as proliferation, apoptosis, tumorigenesis, and cancer progression and metastasis [7][8][9] . Recently, several studies of lncRNAs have indicated that they may play a pivotal role during the initiation and progression of human cancers, including cervical cancer [10][11][12][13] . In the present study, the researchers focused on the lncRNA PVT-1.…”

“…Amplification of 8q24 is one of the most frequent events in a wide variety of malignant diseases. Indeed, PVT-1 generates antiapoptotic activity in human cancers, and overexpression of PVT-1 is a powerful predictor of tumor progression and patient survival in hepatocellular carcinoma [10] ; non-small cell lung cancer [18] ; and colorectal [12] ,ovarian, and breast cancers [15] . Furthermore, PVT-1 has been investigated as a new regulator of various biological processes, such as cell growth, apoptosis, mobility, and invasion [12,15] .…”

Roles of long noncoding RNAs in Hepatocellular Carcinoma

“…Kaneko et al demonstrated that MEG3 interacted with PRC2 mainly through the RBR of JARID2 and MEG3 acts in trans on PRC2 and JARID2 by facilitating their recruitment to a subset of target genes [40]. PVT1 silenced P15/P16 in in trans by recruiting EZH2 [41]. The upregulated EZH2 enforces hepatocellular carcinoma cell proliferation (Figure 2a).…”